The available drugs for treating Leishmaniasis and American trypanosomiasis have high
toxicity and multiple side effects, among other problems. More effective and less toxic …

Drug therapy for leishmaniasis remains a major challenge as currently available drugs have
limited efficacy, induce serious side-effects and are not accessible to everyone. Thus, the …

Ten chalcones were synthesized and tested as potential leishmanicidal and trypanocidal
agents. All tested compounds caused concentration-dependent inhibition of the in vitro …

All currently used first-line and second-line drugs for the treatment of leishmaniasis exhibit
several drawbacks including toxicity, high costs and route of administration. Furthermore …

Chalcones form a class of compounds that belong to the flavonoid family and are widely
distributed in plants. Their simple structure and the ease of preparation make chalcones …

Leishmaniases are endemic diseases in tropical and sub-tropical regions of the world and
are considered by the World Health Organization (WHO) to be among the six most important …

Antileishmanial activities of thirty-five synthetic chalcones have been examined. Among
them, ten compounds (4, 6, 16, 22, 23, 24, 25, 29, 35 and 37) exhibited potent in vitro activity …

Eighteen analogues of an active natural chalcone were synthesized using xanthoxyline and
some derivatives, and these analogues were tested for selective activity against both …

The antileishmanial and antimalarial activity of methoxy-substituted chalcones (1, 3-diphenyl-
2-propen-1-ones) is well established. The few analogs prepared to date where the 3-phenyl …

The in vitro screening of 43 polysubstituted chalcones against Leishmania amazonensis
axenic amastigotes, led to the evaluation of 9 of them in a macrophage-infected model with …